Inovio Pharma gets green signal to test Zika vaccine in human trial
20/06/2016 12:18
June 20 (Reuters) - Drug developer Inovio Pharmaceuticals
Inc INO.O and its partner GeneOne Life Sciences Inc
011000.KS said they had received approval to start an early
stage human trial testing their Zika vaccine.
The early-stage study will enroll 40 healthy subjects and
evaluate safety, tolerability and immune response generated by
the vaccine GLS-5700.
"We plan to dose our first subjects in the next weeks and
expect to report phase I interim results later this year,"
Inovio CEO J Joseph Kim said. urn:newsml:reuters.com:*:nGNXMWJXWa
(Reporting by Amrutha Penumudi in Bengaluru; Editing by Shounak
Dasgupta)
((penumudi.amrutha@thomsonreuters.com; within U.S. +1 646 223
8780 outside U.S. +91 80 6749 4486; Reuters Messaging:
penumudi.amrutha.thomsonreuters.com@reuters.net))
Keywords: HEALTH ZIKA/INOVIO PHARMA